Citius Pharmaceuticals
CTXR
31 hedge funds and large institutions have $1.48M invested in Citius Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
56% more capital invested
Capital invested by funds: $947K → $1.48M (+$530K)
11% more call options, than puts
Call options by funds: $78K | Put options by funds: $70K
11% more funds holding
Funds holding: 28 → 31 (+3)
1.34% more ownership
Funds ownership: 7.4% → 8.73% (+1.3%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$168K |
| 2 |
HCM
Heights Capital Management
San Francisco,
California
|
+$146K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$115K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$22.9K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$18.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$163K |
| 2 |
Squarepoint
New York
|
-$90.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$12.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.57K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$2.47K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SWIM
26
Smallwood Wealth Investment Management
Red Bank,
New Jersey
| $190 | – | – | – |
|
27
BNP Paribas Financial Markets
Paris,
France
| $170 | – | – | – |
|
|
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $127 | – | – | – |
|
29
Morgan Stanley
New York
| $95 | – | – | – |
|
|
LFG
30
Larson Financial Group
St Louis,
Missouri
| $72 | +$41 | +45 | New |
|
|
FC
31
Fairscale Capital
Nashua,
New Hampshire
| $58 | – | – | – |
|
|
32
Squarepoint
New York
| – | -$90.9K | -60,983 | Closed |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| – | -$6.57K | -4,410 | Closed |
|
34
Simplex Trading
Chicago,
Illinois
| – | -$1K | -966 | Closed |
|
|
QC
35
Quent Capital
New York
| – | -$161 | -108 | Closed |
|
36
Barclays
London,
United Kingdom
| – | -$43 | -29 | Closed |
|
CTXR Hedge Fund Activity: Q2 2025 in Review
31 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2025, worth a combined $1.48M — up 56% from $947K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CTXR positions and 5 closed out — a net gain of 3 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $168K. The largest seller was Vanguard Group, cutting an estimated $163K.
- 31 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2025, up from 28 in Q1 2025.
- Funds reported $1.48M of Citius Pharmaceuticals stock for Q2 2025, up 56% quarter-over-quarter.
- 8 funds opened new Citius Pharmaceuticals positions in Q2 2025 and 5 closed out, a net change of +3 holders.
- The largest Citius Pharmaceuticals buyer in Q2 2025 was Cambridge Investment Research Advisors, an estimated $168K added.
- The largest Citius Pharmaceuticals seller in Q2 2025 was Vanguard Group, an estimated $163K sold.
Based on aggregated 13F filings for Q2 2025.